Literature DB >> 20179574

Cytotoxic granule release dominates gag-specific CD4+ T-cell response in different phases of HIV infection.

Elisa Nemes1, Linda Bertoncelli, Enrico Lugli, Marcello Pinti, Milena Nasi, Lisa Manzini, Serena Manzini, Francesca Prati, Vanni Borghi, Andrea Cossarizza, Cristina Mussini.   

Abstract

BACKGROUND: The activity of virus-specific T lymphocytes, among which those capable of a polyfunctional response against the viral protein gag, is crucial to control HIV infection.
OBJECTIVE: The objective of this study is to investigate the polyfunctionality of gag-specific T cells in different phases of HIV infection, analyzing markers related to T-helper cell 1 (Th1) and degranulation/cytotoxicity, and the production of Th1 cytokines in peripheral blood lymphocytes from patients experiencing an acute primary infection, long-term nonprogressors, patients naive for antiretroviral drugs, and patients taking HAART.
MATERIALS AND METHODS: Cells were stimulated with a pool of gag-derived peptides or with a superantigen (staphylococcal enterotoxin B). Using eight-color polychromatic flow cytometry, we analyzed the expression of interleukin-2, interferon-gamma, CD154, and CD107a by CD4 and CD8 T cells.
RESULTS: The main finding was that in all HIV-positive patients, about half gag-specific CD4 T cells were CD107a, that is, able to degranulate. CD4CD154 cells unable to produce Th1 cytokines were the second most represented population. Truly polyfunctional CD4 T cells were very rare and present only in a few long-term nonprogressors. Superantigen stimulation showed that CD4 T lymphocytes from all patients displayed a typical Th response, including interleukin-2 and interferon-gamma production, lacking CD107a expression.
CONCLUSION: In all the aforementioned phases of HIV infection, the large majority of gag-specific CD4 T lymphocytes cannot be identified by the sole expression of interleukin-2 and interferon-gamma, which is early impaired. Degranulation and helper functions other than Th1 cytokine production are the predominant features of HIV-specific CD4 lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179574     DOI: 10.1097/QAD.0b013e328337b144

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  23 in total

1.  Cancer neoantigens targeted by adoptive T cell transfer: private no more.

Authors:  Enrico Lugli; Pia Kvistborg; Giovanni Galletti
Journal:  J Clin Invest       Date:  2019-02-04       Impact factor: 14.808

2.  A novel SIV gag-specific CD4(+)T-cell clone suppresses SIVmac239 replication in CD4(+)T cells revealing the interplay between antiviral effector cells and their infected targets.

Authors:  Victor I Ayala; Matthew T Trivett; Lori V Coren; Sumiti Jain; Patrick S Bohn; Roger W Wiseman; David H O'Connor; Claes Ohlen; David E Ott
Journal:  Virology       Date:  2016-03-25       Impact factor: 3.616

3.  SPICE: exploration and analysis of post-cytometric complex multivariate datasets.

Authors:  Mario Roederer; Joshua L Nozzi; Martha C Nason
Journal:  Cytometry A       Date:  2011-01-07       Impact factor: 4.355

Review 4.  Cytolytic CD4(+) T cells in viral immunity.

Authors:  Damien Z Soghoian; Hendrik Streeck
Journal:  Expert Rev Vaccines       Date:  2010-12       Impact factor: 5.217

5.  The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

Authors:  Mark S de Souza; Silvia Ratto-Kim; Weerawan Chuenarom; Alexandra Schuetz; Somsak Chantakulkij; Bessara Nuntapinit; Anais Valencia-Micolta; Doris Thelian; Sorachai Nitayaphan; Punnee Pitisuttithum; Robert M Paris; Jaranit Kaewkungwal; Nelson L Michael; Supachai Rerks-Ngarm; Bonnie Mathieson; Mary Marovich; Jeffrey R Currier; Jerome H Kim
Journal:  J Immunol       Date:  2012-04-23       Impact factor: 5.422

6.  Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates.

Authors:  Enrico Lugli; Carolyn K Goldman; Liyanage P Perera; Jeremy Smedley; Rhonda Pung; Jason L Yovandich; Stephen P Creekmore; Thomas A Waldmann; Mario Roederer
Journal:  Blood       Date:  2010-07-14       Impact factor: 22.113

7.  Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239.

Authors:  Mauricio A Martins; Nancy A Wilson; Shari M Piaskowski; Kim L Weisgrau; Jessica R Furlott; Myrna C Bonaldo; Marlon G Veloso de Santana; Richard A Rudersdorf; Eva G Rakasz; Karen D Keating; Maria J Chiuchiolo; Michael Piatak; David B Allison; Christopher L Parks; Ricardo Galler; Jeffrey D Lifson; David I Watkins
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

8.  HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term.

Authors:  Benoît Vingert; Daniela Benati; Olivier Lambotte; Pierre de Truchis; Laurence Slama; Patricia Jeannin; Moran Galperin; Santiago Perez-Patrigeon; Faroudy Boufassa; William W Kwok; Fabrice Lemaître; Jean-François Delfraissy; Jacques Thèze; Lisa A Chakrabarti
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

9.  CD8+ and CD4+ cytotoxic T cell escape mutations precede breakthrough SIVmac239 viremia in an elite controller.

Authors:  Benjamin J Burwitz; Juan Pablo Giraldo-Vela; Jason Reed; Laura P Newman; Alexander T Bean; Francesca A Nimityongskul; Philip A Castrovinci; Nicholas J Maness; Enrique J Leon; Richard Rudersdorf; Jonah B Sacha
Journal:  Retrovirology       Date:  2012-11-06       Impact factor: 4.602

10.  Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy.

Authors:  Mark J Dobrzanski
Journal:  Front Oncol       Date:  2013-03-26       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.